Soluble ST2 levels and left ventricular structure and function in patients with metabolic syndrome

Annals of Laboratory Medicine

Volumn 36, Issue 6, 2016, Pages 542-549

  Celic, Vera ^a,b   Majstorovic, Anka ^b   Pencic Popovic, Biljana ^a,b   Sljivic, Aleksandra ^b   Lopez Andres, Natalia ^c   Roy, Ignacio ^d   Escribano, Elena ^d   Beunza, Maite ^d   Melero, Amaia ^c   Floridi, Federico ^e   Magrini, Laura ^e   Marino, Rossella ^e   Salerno, Gerardo ^e   Cardelli, Patrizia ^e   Di Somma, Salvatore ^e  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b University Clinical Hospital Center Dragisa Misovic Dedinje   (Serbia)

^c Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Echocardiography; Left ventricular hypertrophy; Metabolic syndrome; Soluble ST2

Indexed keywords

IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; BLOOD PRESSURE; BODY MASS; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; LINEAR MODELS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ROC CURVE; SEX FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84986266368     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2016.36.6.542     Document Type: Article

References (27)

1. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation 2006.
2. Hunt KJ, ResendezRG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-7.
3. Kim SH. Metabolic syndrome and myocardial contractile reserve. J Cardiovasc Ultrasound 2011;19:174-5.
4. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007;28:553-9.
5. Tadic M, Ivanovic B, Kostic N, Simic D, Matic D, Celic V. Metabolic syndrome and left ventricular function: Is the number of criteria actually important? Med Sci Monit 2012;18:282-9.
6. O'Neil L. The Toll/interleukin-1 receptor domain: A molecular switch for inflammation and host defence. BiochemSoc Trans 2000;28:557-63.
7. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90.
8. Rehman SU, Mueller T, JanuzziJL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am CollCardiol 2008;52:1458-65.
9. Weinberg EO, Shimpo M, De KeulenaerGW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6.
10. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6.
11. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58:1673-81.
12. Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi O, Sliwa K. Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients. J Clin Hypertens 2013;15:899-904.
13. Zeyda M, Wernly B, Demyanets S, Kaun C, Hämmerle M, Hantusch B, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 2013;37:658-65.
14. Fousteris E, Melidonis A, Panoutsopoulos G, Tzirogiannis K, Foussas S, Theodosis-Georgilas A, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 2011;10:101.
15. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study. Clin Chem 2013;59:536-46.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome:ajoint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.
20. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-84.
21. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-93.
22. Oh JK, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. Circ Cardiovasc Imaging 2011;4:444-55.
23. Westcott DJ, DelpropostoJB, Geletka LM, Wang T, Singer K, Saltiel AR, et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009;206: 3143-56.
24. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: Areview. Molecules 2013;18: 15314-28.
25. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: Back to the future. Immunity 2013;39:1003-18.
26. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013;60:16-26.
27. Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013;19:163-8.